PolyPid Announces US Patent Allowance for Sustained Release of Nucleic Acid Matrix Compositions
PolyPid recently announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for US application Serial No. 13/574,040, a patent covering compositions for sustained and/or controlled release of nucleic acid agents. A Notice of Allowance is the formal USPTO notification that an applicant is entitled to a patent under the law.
This allowance follows a notice before allowance, received earlier this year for an Israel patent application No. 210437, corresponding applications of which are currently under examination in the US, China, and Japan. The Israel patent application titled Sustained-Release Drug Carrier Composition covers PolyPid’s drug delivery platform for sustained release of pharmaceutically active agents.
The subject patent application covers PolyPid’s platform for delivery of nucleic acid agents, and specifically relates to compositions comprising a non-covalent matrix of pharmaceutically approved polymers and lipids for sustained release of nucleic acid agents (eg, nucleic acid-based drugs).
PolyPid’s delivery platform enables efficient local delivery and release of the nucleic acid agents directly at a disease site for periods of time ranging from several days to several months. Many types of nucleic acid-based drugs (such as siRNA, etc) may be incorporated in PolyPid’s matrix compositions.
“The patent is an important milestone in the commercialization of PolyPid’s drug delivery platform technology, and is recognition of the platform’s uniqueness,” said Dr. Noam Emanuel, PolyPid’s Chief Technology Officer. “PolyPid’s platform is highly flexible, and can be designed to adapt its combined characteristics and performance to solve a wide range of medical objectives in a variety of clinical fields.”
PolyPid’s intellectual property portfolio includes multiple patent families with pending claims directed to PolyPid’s drug delivery platform, implants, and medical devices.
A recent clinical study with PolyPid’s leading medical device, BonyPid, an antibiotic-loaded bone substitute, in severe, contaminated open fractures has shown early bone recovery, early soft tissue recovery, no amputations, and high safety profile – no infection in the target fracture.
Founded in 2008 and located in Israel, PolyPid offers proprietary medical device and drug delivery solutions. Polypid’s pharma solutions optimize drug delivery by enabling a controlled, constant, and prolonged release of drug. For more information, visit www.polypid.com.
Total Page Views: 753
